Navigation Links
Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
Date:10/19/2007

CHICAGO, Oct. 19 /PRNewswire/ -- Actelion Ltd (SWX: ATLN) today announced multiple presentations regarding Tracleer(R) (bosentan), including new Phase 3 data assessing the efficacy and safety of Tracleer in combination with sildenafil, and data obtained from the first 1,500 patients with pulmonary arterial hypertension (PAH) enrolled in the REVEAL(TM) (Registry to EValuate Early And Long-term PAH Disease Management) Registry. The presentations and publications are part of the proceedings at CHEST 2007, the annual meeting of the American College of Chest Physicians, being held October 20-25, 2007 at McCormick Place in Chicago, IL. The company will be exhibiting at booth # 239 in the Exhibit Hall.

The presentations and abstracts -- including date and location for each -- are as follows:

Tuesday, October 23, 2007, 12:30 p.m. - 2:00 p.m.

Session: Pulmonary Vascular Disease: Evaluation and Treatment, ID #858

Oral Presentation: REVEAL Registry: Baseline Characteristics of the First

Enrolled Patients

Location: Convention Center E264

Presenter: David Badesch, MD

Abstract #: 5982

Tuesday, October 23, 2007, 2:30 p.m. - 4:00 p.m.

Session: Pulmonary Vascular Disease: Pulmonary HTN, ID # 900

Oral Presentation: Bosentan improves hemodynamics in patients receiving

background Sildenafil treatment: results from EARLY, a randomized,

double-blind, placebo controlled study in patients with mildly

symptomatic pulmonary arterial hypertension

Location: Convention Center E266

Presenter: Lewis Rubin, MD

Abstract #: 5356

Session: Pulmonary Vascular Disease : Pulmonary HTN, ID # 900

Oral Presentation: Acute hemodynamic effect of Sildenafil in comparison

with inhaled nitric oxide in patients receiving Bosentan therapy for

pulmonary arterial hypertension (COMPASS-1)

Location: Convention Center E266

Presenter: Nazzareno Galie, MD

Abstract #: 5482

Wednesday, October 24, 2007, 12:30 p.m. - 2:00 p.m.

Session: Pulmonary Vascular Disease: Pulmonary HTN Evaluation and

Treatment, ID #893

Poster Presentation: REVEAL Registry: Treatment History and Treatment at

Baseline

Location: Convention Center, Exhibit Hall

Presenter: Michael McGoon, MD

Poster #: 585

Abstract #: 6023

Session: Pulmonary Vascular Disease: Pulmonary HTN Evaluation and

Treatment, ID #893

Poster Presentation: REVEAL Registry: Medical History and Time to

Diagnosis of Enrolled Patients

Location: Convention Center, Exhibit Hall

Presenter: C. Gregory Elliott, MD

Poster #: 584

Abstract #: 6036

Session: Pulmonary Vascular Disease: Pulmonary HTN Evaluation and

Treatment, ID #893

Poster Presentation: Goal-Directed Combination Therapy in Pulmonary

Arterial Hypertension (PAH): Study Design of COMPASS-3

Location: Convention Center, Exhibit Hall

Presenter: Fernando Torres, MD

Poster #: 573

Abstract #: 5963

About Tracleer(R) in Pulmonary Arterial Hypertension (PAH)

Tracleer(R) (bosentan), the first oral dual endothelin receptor antagonist, is approved for the treatment of pulmonary arterial hypertension (PAH) and made available by Actelion subsidiaries in the United States, the European Union, Japan, Australia, Canada, Switzerland and other markets worldwide.

Requires attention to two significant safety concerns: Potential for serious liver injury (including rare cases of liver failure and unexplained hepatic cirrhosis in a setting of close monitoring) -- Liver monitoring of all patients is essential prior to initiation of treatment and monthly thereafter. High potential for major birth defects -- Pregnancy must be excluded and prevented by two forms of birth control; monthly pregnancy tests should be obtained. Because of these risks, Tracleer is only supplied through a controlled distribution.

About Actelion Pharmaceuticals

Actelion Pharmaceuticals has pioneered research and development in the pulmonary arterial hypertension (PAH) disease area. More than 40,000 PAH patients have been prescribed Actelion's product Tracleer(R) (bosentan), an orally available dual endothelin receptor antagonist for patients with World Health Organization (WHO) Class III or IV PAH. Tracleer was approved in 2001 as the first oral treatment for PAH, and is currently approved in the U.S., the European Union, and other markets worldwide. In January 2007, Actelion acquired CoTherix, Inc., whose product Ventavis(R) is approved and marketed in the United States for the treatment of patients with NYHA Class III or IV PAH.


'/>"/>
SOURCE Actelion Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
(Date:6/22/2016)... June 22, 2016 Research and Markets has ... report to their offering. ... 2014 from $29.3 billion in 2013. The market is expected to ... from 2015 to 2020, increasing from $50.6 billion in 2015 to ... forecasts during the forecast period (2015 to 2020) are discussed. As ...
Breaking Biology Technology:
(Date:6/1/2016)... -- Favorable Government Initiatives Coupled With Implementation ... to Boost Global Biometrics System Market Through 2021  ... " Global Biometrics Market By Type, By End ... - 2021", the global biometrics market is projected to ... growing security concerns across various end use sectors such ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
Breaking Biology News(10 mins):